A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

Description

The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.

Conditions

Renal Impairment

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.

A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics of Mezigdomide (BMS-986348, CC-92480) in Adult Participants With Normal Renal Function, Severe Renal Impairment, and End-stage Renal Disease

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

Condition
Renal Impairment
Intervention / Treatment

-

Contacts and Locations

Miami Lakes

PANAX, Miami Lakes, Florida, United States, 33014

Orlando

Omega Research Group - Orlando, Orlando, Florida, United States, 32808

Orlando

Orlando Clinical Research Center OCRC, Orlando, Florida, United States, 32809

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to 82 Years

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    Yes

    Collaborators and Investigators

    Celgene,

    Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb

    Study Record Dates

    2025-03-05